UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): April 8, 2016

TONIX PHARMACEUTICALS HOLDING CORP.

(Exact name of registrant as specified in its charter)

Nevada (State or Other Jurisdiction of Incorporation) 001-36019 (Commission File Number) 26-1434750 (IRS Employer Identification No.)

509 Madison Avenue, Suite 306, New York, New York 10022 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (212) 980-9155

Copy of correspondence to:

Marc J. Ross, Esq. James M. Turner, Esq. Sichenzia Ross Friedman Ference LLP 61 Broadway New York, New York 10006 Tel: (212) 930-9700 Fax: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Tonix Pharmaceuticals Holding Corp. (the "Company") intends to utilize an updated investor presentation to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain non-public information. A copy of the presentation is filed as Exhibit 99.01.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01, is furnished pursuant to, and shall not be deemed to be "filed" for the purposes of, Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information contained in Item 7.01 of this Current Report shall not be incorporated by reference into any registration statement or any other document filed pursuant to the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing. By filing this Current Report on Form 8-K and furnishing the information contained in this Item 7.01, including Exhibit 99.01, the Company makes no admission as to the materiality of any such information that it is furnishing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.01 Corporate Presentation by the Company for April 2016*

* Furnished herewith.

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TONIX PHARMACEUTICALS HOLDING CORP.

Date: April 8, 2016

By: /s/ SETH LEDERMAN

Seth Lederman Chief Executive Officer

Exhibit 99.01



NASDAQ: TNXP

Investor Presentation April 2016

Version: P0013-04-8-16

© 2016 Tonix Pharmaceuticals Holding Corp.

Cautionary note on forward-looking statements

Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our possible need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain U.S Food and Drug Administration clearances or approvals and noncompliance with its regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. The forward-looking statements in this presentation are made as of the date of this presentation, even if subsequently made available by the Company on its website or otherwise. Tonix does not undertake an obligation to update or revise any forward-looking statement, except as required by law. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission (the "SEC") on March 3, 2016, and future periodic reports filed with the SEC on or after the date hereof. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.



Developing innovative medicines for large and growing markets

Targeting two common central nervous system disorders

- One clinical-stage proprietary candidate targeting two indications
- Differentiated product with potential for sustainable competitive advantages

2016 to reveal results from two clinical trials


- Fibromyalgia Phase 3 to report in 3Q
 - Central pain disorder
 - Phase 3 study (AFFIRM) enrolling
- Post-traumatic stress disorder Phase 2 to report in 2Q (2nd Half of May)
 - Serious mental health problem¹
 - Clinical phase of Phase 2 (AtEase) in military-related PTSD completed

All intellectual property owned by Tonix

¹Schnurr, PP et al., Contemporary Clinical Trials 2015;41:75.



Pipeline led by TNX-102 SL for fibromyalgia




* Tonmya[™] has been conditionally accepted by the FDA as the proposed tradename of TNX-102 SL for fibromyalgia.

NDA = New Drug Application; FDA = U.S. Food and Drug Administration. TNX-102 SL (cyclobenzaprine HCl sublingual tablets, 2.8 mg) is an Investigational New Drug and is not approved for any indication.



4

Concept: Fibromyalgia is inappropriate central pain signaling in the absence of peripheral injury



Volkswagen Check Engine [Photograph]. (2011, October 14). Wikipedia



5

Fibromyalgia is a chronic, debilitating disorder that imposes a significant societal and economic burden

Fibromyalgia is considered neurobiological disorder characterized by¹:

 Chronic widespread pain
 Fatigue
 Nonrestorative sleep
 Diminished cognition

 Believed to result from amplified sensory and pain signaling in central nervous system¹
 Causes significant impairment in all areas of life²

 Lower levels of health-related quality of life – reduced daily functioning
 Interference with work (loss of productivity, disability)


Inflicts substantial strain on the healthcare system

- Average patient has 20 physician office visits per year³
- Annual direct medical costs are twice those for non-fibromyalgia individuals⁴

¹Phillips K & Clauw DJ, Best Pract Res Clin Rheumatol 2011;25:141. ²Schaefer et al., Pain Pract, 2015. ³Robinson et al, Pain Medicine 2013;14:1400. ⁴White et al, J Occupational Environ Med 2008;50:13.



Fibromyalgia is a prevalent disorder but remains underdiagnosed



⁴Independent study conducted by IMS Consulting Group, April 2015 using IMS MIDAS (exmanufacturing price), factored for fibromyalgia based on IMS National Disease and Therapeutic Index (NDTI).




7

Fewer than half of those treated for fibromyalgia receive sustained benefit from the three FDA-approved drugs

8

- The treatment objective is to restore functionality and quality of life by broadly improving symptoms while avoiding significant side effects
- The majority fail therapy due to lack of a response or poor tolerability¹



Large need for new fibromyalgia therapies that provide broad symptom improvement with better tolerability

- Currently-approved medications may have side effects that limit long-term use¹
 - Many patients skip doses or discontinue altogether within months of treatment initiation

Medication-related side effects may be similar to fibromyalgia symptoms

High rates of discontinuation, switching and augmentation

- Attempt to treat multiple symptoms and/or avoid intolerable side effects
- Average of 2-3 medications used simultaneously²
- The typical patient has tried six different medications³

Substantial off-label use of narcotic painkillers and prescription sleep aids³

¹Nuesch et al, Ann Rheum Dis 2013;72:955-62. ²Robinson RL et al, Pain Medicine 2012;13:1366. ³"Patient Trends: Fibromyalgia", Decision Resources, 2011.



9

Tonix is developing TNX-102 SL for fibromyalgia

10

- Advanced sublingual tablet containing low-dose cyclobenzaprine (CBP)
 - Designed for daily bedtime administration with no titration
 - Efficient transmucosal absorption
 - Avoidance of first-pass metabolism reduces formation of long-lived metabolite

TNX-102 SL's pharmacologic action is believed to improve sleep quality

- Non-restorative sleep is a common clinical and diagnostic feature of fibromyalgia¹
- Evolving understanding of the role of sleep in pain control and fibromyalgia development²
- TNX-102 SL targets receptors believed to play key roles in sleep physiology
- Phase 2b "BESTFIT" study was successfully completed in 3Q14

Top line data from ongoing Phase 3 "AFFIRM" study expected to report in 3Q16

¹Swick TJ, Ther Adv Musculoskel Dis 2011;3:167-178. ²Choy EH, Nat Rev Rheumatol; 2015: 11:513-520. TNX-102 SL (cyclobenzaprine HCl sublingual tablets, 2.8 mg) is an Investigational New Drug and is not approved for any indication.



Phase 2b "BESTFIT" study of TNX-102 SL in fibromyalgia

BESTFIT = <u>BE</u>dtime <u>Sublingual TNX-102 SL as Fibromyalgia Intervention</u> <u>Therapy</u>

- Randomized, double-blind, placebo-controlled trial
- 2010 American College of Rheumatology diagnostic criteria for fibromyalgia
- 205 participants randomized 1:1 at 17 U.S. sites
- Sublingual tablet of TNX-102 SL 2.8 mg or placebo daily at bedtime for 12 weeks
- Evaluated measures of pain, sleep quality, and other assessments of fibromyalgia

TNX-102 SL (cyclobenzaprine HCl sublingual tablets, 2.8 mg) is an Investigational New Drug and is not approved for any indication. © Copyright 2016 Tonix Pharmaceuticals



BESTFIT results on key clinical endpoints

<i>p</i> value	
0.033	
0.005	
0.025	
0.014	
 p < 0.05 → statistically significant PROMIS = Patient-Reported Outcomes Measurement Information S PGIC = Patient Global Impression of Change FIQ-R = Fibromyalgia Impact Questionnaire - Revised 	
of	

© Copyright 2016 Tonix Pharmaceuticals

12

PHARMACEUTICALS

TNX-102 SL safety and tolerability profile in the BESTFIT study

No serious adverse events (SAE) reported with TNX-102 SL

Systemic adverse events reported by at least 3% of the total BESTFIT

population		TNX-102 SL (N=103)	Placebo (N=101)	Total (N=204)
	Somnolence	1.9	6.9	4.4
	Dry Mouth	3.9	4.0	3.9
	Back Pain	4.9	3.0	3.9
	Nausea	4.9	2.0	3.4
	Sinusitis	3.9	3.0	3.4

Most frequent local adverse events were administration site reactions


- Previously reported in Phase 1 studies; no detectable bias on efficacy results
- Transient tongue numbness (44% TNX-102 SL vs. 2% placebo)
- Abnormal taste (8% TNX-102 SL vs. 0% placebo)

Trial completion rates of 86% with TNX-102 SL vs. 83% with placebo

Source: Phase 2b BESTFIT study data – Preliminary Study Report. TNX-102 SL (cyclobenzaprine HCl sublingual tablets, 2.8 mg) is an Investigational New © Copyright 2016 Tonix Pharmaceuticals Drug and is not approved for any indication.




TNX-102 SL in Phase 3 clinical development for fibromyalgia



TNX-102 SL (cyclobenzaprine HCl sublingual tablets, 2.8 mg) is an Investigational New Drug and is not approved for any indication.



TNX-102 SL in Phase 2 development for post-traumatic stress disorder (PTSD)



15

* Tonmya" has been conditionally accepted by the FDA as the proposed tradename of TNX-102 SL for fibromyalgia.

NDA = New Drug Application; FDA = U.S. Food and Drug Administration. TNX-102 SL (cyclobenzaprine HCl sublingual tablets, 2.8 mg) is an Investigational New Drug and is not approved for any indication.

PTSD is a chronic stress disorder triggered by a traumatic event

PTSD is characterized by:

- re-experiencing the triggering event
- situation/stimulus avoidance
- negative alterations in mood/cognition
 hypervigilance (anxiety, difficulty sleeping)
- Considered a stress response, but prolonged and does not resolve with time
 - 20% of women and 8% of men who experience significant trauma develop PTSD¹


Associated with significant life disruption

- Social isolation, inability to maintain employment, loss of independent living
- Unpredictable acts of violence, suicidal thoughts

¹ Kessler et al, Arch Gen Psychiatry 1995;52:1048.



PTSD is a prevalent problem for both civilians and the military






PTSD veteran population: recent conflicts only

18


Veteran Administration (VA) records indicate that 20% of veterans from recent conflicts will have potential or provisional PTSD Veterans From Recent Conflicts



Source: Report on VA Facility Specific Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND) Veterans Diagnosed with Potential or Provisional PTSD. Cumulative from 1st Qtr FY 2002 through Qtr FY 2014 (October 1, 2001 – March 31, 2014)



PTSD veteran population: all conflicts



¹Bernardy et al., J Clin Psychiatry, 2012, 73:297-303 ²Bowe et al, J Dual Diagnosis, 2014, 11:22-32



Significant gap in current therapeutic landscape for PTSD

Medicines approved for PTSD often provide inadequate and/or inconsistent benefit

- Limited to two SSRI antidepressants, both of which carry suicidality warnings
- U.S. Institute of Medicine (IOM) concluded that evidence of treatment effect is low1
- Lack of efficacy evidence in those with a history of combat-related trauma2

Sleep dysfunction in PTSD is resistant to currently-approved options

- 95%+ report insomnia, 83% report recurrent dreams of the trauma³
- Correlated with disease severity, depression, substance abuse and suicide⁴
- Drugs approved for insomnia have been shown to not improve PTSD sleep dysfunction

Off-label use of anxiolytics, sedative-hypnotics, and antipsychotics is common⁵

- Limited evidence of effectiveness; may be harmful
- May interfere with other treatments such as cognitive behavioral therapy (CBT)

SSRI = selective serotonin reuptake inhibitor.

¹ Marshall et al, Am J Psychiatry 2001;158:1982.

² Jonathan Davidson, personal communications, 2014.

³ Green B. Post-traumatic stress disorder: Symptom profiles in men and women. Curr Med Res Opin 2003;19:200-4.

⁴ Germain et al, J Anxiety Disord 2005;19:233; Krakow et al, J Nerv Ment Dis 2002;190:442.

⁵ Bernardy et al., J Clin Psychiatry, 2012, 73:297-303.

TONIX

© Copyright 2016 Tonix Pharmaceuticals

٠

Targeting sleep quality is a novel mechanism of action in PTSD therapy

- PTSD patients complain of sleep disturbance as a core symptom¹ ٠ - Distressing dreams (nightmares) are part of "re-experiencing" Avoidance can be of bed/sleep due to fear of nightmares Restless sleep is part of the "hyper-arousal" cluster of PTSD diagnostic criteria Sleep disturbance after trauma is linked to onset of PTSD² • Sleep disturbance also correlates with depression, substance abuse and suicidal . behaviors in PTSD³ TNX-102 SL is a tricyclic molecule that potently targets three molecular . mechanisms⁴, each of which is associated with treating aspects of disturbed sleep, enhancing sleep quality Blocks the 5-HT_{2A} receptor (like trazodone) -Blocks the a1 adrenergic receptor (like prazosin) _ Blocks the H1 receptor (like low-dose doxepin) ¹ American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, 2013. ² Koren et al, AJP 159:855-857, 2002; Mellman et al, AJP 159:1969-1701, 2002.
 - ³ Germain, AJP 170:372-382, 2013; McHugh et al, J Traumatic Stress 27:82-89, 2014 Betts et al, Journal of Anxiety Disorders 27:735-41, 2013.

⁴ Daugherty et al, Society of Biological Psychiatry 70th Annual Scientific Convention, May 14-16, 2015 Toronto, Ontario, Canada.

TNX-102 SL (cycloberzaprine HCl sublingual tablets, 2.8 mg) is an Investigational New Drug and is not approved for any indication.



21

Tonix's AtEase study in military-related PTSD: primary endpoint and power considerations

22

- Primary endpoint is the change from baseline of the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
 - Raters are trained, certified, and monitored for reliability throughout the study
- Powered at ≥80% to detect an effect size of 0.5 (Cohen's d)
 - Translates to detection of difference of approximately 10 points (8.5-11.5) at group level between TNX-102 SL 2.8 mg and placebo for the reduction in total CAPS-5 score
 - Assuming that approximately 66 patients complete the 12 week study in each of the TNX-102 SL and placebo groups
 - A 10-point difference on CAPS-5 between treatment groups is approximately equivalent to a 17-point difference on CAPS-4 for DSM-IV

TNX-102 SL (cyclobenzaprine HCl sublingual tablets, 2.8 mg) is an Investigational New Drug and is not approved for any indication.



Limitations of current FDA-approved pharmacotherapies for PTSD

- Britain's National Institute for Clinical Excellence (NICE) National Clinical Practice Guideline for management of PTSD reported an effect size in paroxetine trials of 0.42 and for sertraline trials, the effect size was 0.26¹
 A priori, NICE had set a threshold of 0.5 as an effect size that would indicate a clinically meaningful effect on PTSD
 NICE stated that neither of these two FDA-approved therapies had conclusive evidence to determine if there was a clinically important difference from placebo
 Limited treatment response to SSRIs in males and US military

 In a review of sertraline registration trials, no effect on PTSD demonstrated for male
 - subgroups in an FDA-conducted post-hoc analysis
 None of the four double-blind placebo-controlled trials of SSRIs in U.S. military veterans demonstrated any evidence that SSRIs were superior to placebo²

¹ National Clinical Practice Guideline No. 26, National Institute for Clinical Excellence, 2005.
 ² Davidson J, Journal of Psychopharmacology, 2015.

TNX-102 SL's potential as a treatment for PTSD is supported by clinical evidence and pharmacology

- TNX-102 SL is active on receptor sites believed to have treatment potential for sleep problems in PTSD
 - Targeted receptors include 5-HT2a, alpha-1 adrenergic, and histamine-1 receptors
- Efficacy of "tricyclic" drug class in PTSD is supported by clinical data¹
 Oral tricyclics have side effects that limited their use
- Improvements observed in BESTFIT study relate to PTSD core symptoms²


Outcome Measure at Week 12 in BESTFIT	<i>p</i> value	
PROMIS Sleep Disturbance	0.005	p < 0.05 →
FIQ-R Anxiety Item	0.012	statistically significant
FIQ-R Sensitivity Item	0.020	

1 Davidson J, J Psychopharm 2015;29;264. 2 Phase 2b BESTFIT study data. TNX-102 SL (cyclobenzaprine HCl sublingual tablets, 2.8 mg) is an Investigational New

Drug and is not approved for any indication.



Phase 2 "AtEase" trial of TNX-102 SL in PTSD is fully enrolled



Intellectual property

26

Wholly-owned by Tonix with no obligations to others

TNX-102 SL

Fibromyalgia, PTSD


- Composition-of-matter (eutectic)
 - Patents filed
 - Protection expected to 2034
- Pharmacokinetics (PK)
 - Patents filed
 - Protection expected to 2033
- Method-of-use
 - Fibromyalgia: patents issued, 2020 expiry
 - PTSD: patents filed

TNX-102 SL (cyclobenzaprine HCl sublingual tablets, 2.8 mg) is an Investigational New Drug and is not approved for any indication. © Copyright 2016 Tonix Pharmaceuticals



Cyclobenzaprine is detected in plasma within minutes following sublingual TNX-102 SL

Plasma Concentration Versus Time of TNX-102 SL Compared to Cyclobenzaprine IR




TNX-102 SL (cyclobenzaprine HCl sublingual tablets, 2.8 mg) is an Investigational New Drug and is not approved for any indication. © Copyright 2016 Tonix Pharmaceuticals




27

Formulation with base increases systemic absorption of sublingual cyclobenzaprine¹

Concentration gradient increases diffusion of free base across oral mucosa (Le Chatelier's Principle) 28



Proprietary cyclobenzaprine hydrochloride eutectic mixture stabilizes tablet formulation¹



Financial overview

NASDAQ: TNXP

Cash, cash equivalents, and marketable securities reported at December 31, 2015	\$ 43.0 million
Cash used in operations in 2015	\$ 42.5 million
Shares outstanding (April 7, 2016)	18.9 million



30

Management team

Seth Lederman, MD vela Fusilev (levoleucovorin) for injection TARGENT President & CEO Bruce Daugherty, PhD, MBA MERCK Roche Chief Scientific Officer Gregory Sullivan, MD New York State Psychiatric Institute Columbia University Chief Medical Officer **Bradley Saenger, CPA Shire** VERTEX Chief Financial Officer Steward pwc A Jessica Edgar Morris American Deutsche Bank svb > EVP, Administration Capital Silicon Valley Bank **Ronald Notvest, PhD** Wyeth Rapamune[•] **Evidec** EVP, Commercial Planning & Development sirolimus anglaties © Copyright 2016 Tonix Pharmaceuticals

31

Board of directors

Seth Lederman, MD Chairman

Stuart Davidson Labrador Ventures, Alkermes, Combion

Patrick Grace Apollo Philanthropy, WR Grace, Chemed

Donald Landry, MD, PhD Chair of Medicine, Columbia University Ernest Mario, PhD ALZA, Glaxo, Reliant Pharma

Charles Mather BTIG, Janney, Jefferies, Cowen, Smith Barney

John Rhodes NYSERDA, NRDC, Booz Allen Hamilton

Samuel Saks, MD Jazz Pharma, ALZA, Johnson & Johnson

© Copyright 2016 Tonix Pharmaceuticals



32

TNX-102 SL – Fibromyalgia

	May 2015	Began Phase 3 AFFIRM study
V	November 2015	Presented additional data from Phase 2b BESTFIT study
		at ACR Meeting
	Q3 2016	Report top-line results from AFFIRM study
TN	IX-102 SL – Post	-Traumatic Stress Disorder
1	December 2015	Entered into CRADA with USAMMDA
-	December 2015	Papartad completion of annollment in Dhace 2 AtEace stud

- ☑ December 2015 Reported completion of enrollment in Phase 2 AtEase study
- □ 2nd Half May 2016 Report top-line results from AtEase study







NASDAQ: TNXP

509 Madison Avenue New York, NY 10022 (212) 980-9155

www.tonixpharma.com